anti cox2 antibody  (Cell Signaling Technology Inc)

Journal: Biomedical Reports

Article Title: Peroxiredoxin 4 suppresses ferroptosis in esophageal squamous cell carcinoma by activating the phosphoinositide 3-kinase  signaling pathway

doi: 10.3892/br.2026.2133

Figure Lengend Snippet: PRDX4 is an important regulator of ferroptosis in ESCC cells. (A) Determination of MDA, LPO and GSH contents in KYSE270 cells after transfection with PRDX4 siRNA. (B) Western blot analysis of the protein levels of GPX4, SLC7A11 and PTGS2 in KYSE270 cells transfected with PRDX4 siRNA. (C) The relative protein levels of GPX4, SLC7A11 and PTGS2 in KYSE270 cells transfected with PRDX4 siRNA. (D) Determination of MDA, LPO and GSH contents in KYSE30 cells after transfection with pcDNA3.1-PRDX4. (E) Western blot analysis of the protein levels of GPX4, SLC7A11 and PTGS2 in KYSE30 cells transfected with pcDNA3.1-PRDX4. (F) The relative protein levels of GPX4, SLC7A11 and PTGS2 in KYSE30 cells transfected with pcDNA3.1-PRDX4. (G) Detection of the levels of MDA, LPO and GSH in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (H) Western blot analysis of the protein expression levels of GPX4, SLC7A11 and PTGS2 in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (I) The relative protein levels of GPX4, SLC7A11 and PTGS2 in the control group, PRDX4 siRNA group and PRDX4 siRNA plus Fer-1 group in KYSE270 cells. (J) Detection of the levels of MDA, LPO and GSH in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. (K) Western blot analysis of the protein expression levels of GPX4, SLC7A11 and PTGS2 in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. (L) The relative protein levels of GPX4, SLC7A11 and PTGS2 in the pcDNA3.1 group, pcDNA3.1-PRDX4 group and pcDNA3.1-PRDX4 plus erastin group in KYSE30 cells. ** P<0.01, *** P<0.001 and **** P<0.0001, indicate statistical significance. PRDX4, peroxiredoxin 4; ESCC, esophageal squamous cell carcinoma; siRNA, small interfering RNA; MDA, malondialdehyde; LPO, lipid peroxidation; GSH, glutathione; GPX4, glutathione peroxidase 4; SLC7A11, solute carrier family 7 member 11; PTGS2, prostaglandin-endoperoxide synthase 2; Fer-1, ferrostatin-1; ns, not significant.

Article Snippet: The primary antibodies were as follows: Anti-PRDX4 (1:2,000 dilution; cat. no. 10703-1-AP), anti-E-cadherin (1:20,000 dilution; cat. no. 20874-1-AP), anti-N-cadherin (1:2,000 dilution; cat. no. 22018-1-AP), anti-Vimentin (1:20,000 dilution; cat. no. 10366-1-AP), and anti-GPX4 (1:1,000 dilution; cat. no. 30388-1-AP; all from Proteintech Group, Inc.), anti-solute carrier family 7 member 11 (SLC7A11; 1:1,000 dilution; cat. no. DF12509; Affinity Biosciences, Ltd.), anti-prostaglandin-endoperoxide synthase 2 (PTGS2; 1:1,000 dilution; cat. no. 27308-1-AP; Proteintech Group, Inc.), anti-p-PI3K (1:1,000 dilution; cat. no. AP0427; ABclonal Biotech Co., Ltd.), anti-PI3K (1:1,000 dilution; cat. no. A19742; ABclonal Biotech Co., Ltd.), anti-p-AKT (1:2,000 dilution; cat. no. 28731-1-AP; Proteintech Group, Inc.), anti-AKT (1:2,000 dilution; cat. no. 10176-2-AP; Proteintech Group, Inc.) and anti-β-actin (1:2,000 dilution; cat. no. 20536-1-AP; Proteintech Group, Inc.).

Techniques: Transfection, Western Blot, Control, Expressing, Small Interfering RNA

Journal: Materials Today Bio

Article Title: Sequential delivery of sinigrin and dabigatran by an in situ self-stabilizing dynamic hydrogel attenuates intervertebral disc degeneration

doi: 10.1016/j.mtbio.2026.102827

Figure Lengend Snippet: DS@CAD ameliorates TNF-α-induced imbalance between anabolism and catabolism in HNPCs. (A) Heatmap visualization of RT‒qPCR data showing the expression of ECM synthesis markers (Col2a1, COL1 and Acan), degradation markers (Adamts4 and MMP13), and inflammation indicators (COX2 and iNOS) after different treatments. (B) Western blot analysis was used to evaluate ECM synthesis proteins (Col2a1, COL1 and Acan), degradation proteins (Adamts4 and MMP13), and inflammation markers (COX2 and iNOS) following different interventions. (C–H) Quantitative analysis of the Western blot data. (I, J) Alcian blue and Safranin O staining of NPCs after various treatments (scale bar: 200 μm). (K) IF of Col2a1, MMP13, and COX2 in NPCs after different treatments (scale bar: 20 μm). (L, M). Relative statistics of Alcian and Safranin O staining. (N–P) Statistical analysis of fluorescence intensity in the IF analysis. (n = 3; ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001).

Article Snippet: Cells in glass-bottomed dishes were sequentially treated: fixed with 4 % paraformaldehyde for 20 min, permeabilized with 0.5 % Triton X-100 for 15 min, and blocked with 5 % (w/v) bovine serum albumin for 30 min, before incubation with primary antibodies against Col2a1 (1:100, A19308, abclone, China), MMP13 (A1606, abclone, China), COX2 (27308-1-AP, Proteintech, China).

Techniques: Expressing, Western Blot, Staining, Fluorescence

Journal: Materials Today Bio

Article Title: Sequential delivery of sinigrin and dabigatran by an in situ self-stabilizing dynamic hydrogel attenuates intervertebral disc degeneration

doi: 10.1016/j.mtbio.2026.102827

Figure Lengend Snippet: DS@CAD protects against IDD in a surgically induced model in vivo. (A) Procedural flow for in vivo experiments in rats (created using BioRender.com ). (B) Micro-CT and (C) MR images of the punctured disc segments at 4 weeks and 8 weeks posttreatment. (D) Representative images of H&E staining in each group at 4 and 8 weeks. (E) Representative images of SO&FG staining in each group at 4 and 8 weeks. (F) IHC staining image of Col2a1, MMP13 and COX2 at 8 weeks. (G, H) Differences in the DHI between each group at 4 and 8 weeks. (I) Quantitative analysis of the average grey value of IVDs. (J) Heatmap showing Pfirrmann grade differences within each group at 4 and 8 weeks. (K) Histological grades of the different groups at weeks 4 and 8. (n = 5; ∗P < 0.05, ∗∗P < 0.01, and ∗∗∗P < 0.001).

Article Snippet: Cells in glass-bottomed dishes were sequentially treated: fixed with 4 % paraformaldehyde for 20 min, permeabilized with 0.5 % Triton X-100 for 15 min, and blocked with 5 % (w/v) bovine serum albumin for 30 min, before incubation with primary antibodies against Col2a1 (1:100, A19308, abclone, China), MMP13 (A1606, abclone, China), COX2 (27308-1-AP, Proteintech, China).

Techniques: In Vivo, Micro-CT, Staining, Immunohistochemistry